Human body weight

Healthy Foods Deliver Defense Against Cancer and Heart Disease

Retrieved on: 
Wednesday, February 21, 2024
Buffalo, Blood pressure, Diabetes, Breast cancer, Consumer, Effect, Copper, Research, Magnesium, Zinc, Cholesterol, Blood, Obesity, Mineral, Food, Vitamin, Weight loss, Glycemic, Prostate, Plant, Harvard University, Purdue University, Conditional sentence, Exercise, Plaque, Human body weight, Phytosterol, Niacin, Risk, Potassium, Vitamin E, Seed, Types of plant oils, Radiation, Olive oil, Health, Folate, University, Death, Nutrient, Fasting, Medicine, Artery, Physiology, Heart, Resveratrol, Food industry, Pinterest, Meal, Brain, Fats, HDL, Cancer, Randomized controlled trial, Dietary supplement

The vitamins and minerals in "good-for-you" nourishment provide energy for daily living, help the body grow and repair and can prevent diet-related illnesses like cancer and heart disease.

Key Points: 
  • The vitamins and minerals in "good-for-you" nourishment provide energy for daily living, help the body grow and repair and can prevent diet-related illnesses like cancer and heart disease.
  • According to the Centers for Disease Control and Prevention, heart disease is the leading cause of death in the United States, followed by cancer.
  • There are a number of factors that can increase the risk of developing heart disease, including high blood pressure, high cholesterol, obesity and diabetes .
  • Research shows that in addition to inhibiting colon, prostate and breast cancer cell growth, they can also protect against heart disease.

EnGeneIC’s breakthrough Armed Nanocell Drug Conjugate (ANDC) treatment shows promising results in Pancreatic cancer patients who have run out of treatment options

Retrieved on: 
Monday, November 27, 2023
Drug resistance, McDiarmid, Quality of life, Immunotherapy, Survival, Heel, Immune system, Human body weight, Lead, Neoplasm, Clinical trial, Cancer, Rated R, EDV, Pancreatic cancer, Conditional sentence, PDAC, Toxicity, Weight gain, Optimism, Patient, Therapy, Pharmaceutical industry

The trial results highlight a significant advance in the treatment landscape for PDAC:

Key Points: 
  • The trial results highlight a significant advance in the treatment landscape for PDAC:
    Unprecedented Survival Rates.
  • The trial demonstrated a substantial increase in median overall survival for patients, with 88% of participants surpassing at least double the historical survival rates.
  • Remarkably, more than 80% of patients receiving the EDV treatment either maintained or experienced weight gain.
  • Joint-CEO and Director of EnGeneIC, Dr Jennifer MacDiarmid said, “We are very excited about the results of our Carolyn Trial.

Carmot Therapeutics Announces Two Oral Presentations Featuring Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 59th European Association for the Study of Diabetes (EASD) Annual Meeting

Retrieved on: 
Tuesday, September 26, 2023
Volunteering, Obesity, Human body weight, MOA, Therapy, T1D, Weight loss, Clinical trial, Type 2 diabetes, Pharmacokinetics, PYY, DSM-IV codes, Patient, CEST, Overweight, GIP, European Association for the Study of Diabetes, T2D, Diabetes, Medical imaging, Birth control, Communications satellite, Vaccine, Philosopher's stone

BERKELEY, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics Inc. (Carmot), a clinical-stage biotechnology company dedicated to delivering life-changing therapeutics for people with metabolic diseases, today announced two oral presentations to take place at the European Association for the Study of Diabetes Annual Meeting from October 2-6, 2023 in Hamburg, Germany. Details regarding the clinical data presentations are as follows:

Key Points: 
  • Carmot expects to initiate additional Phase 2 trials for obesity and T2D.
  • Carmot has recently initiated an additional Phase 1 MOA study in adults with overweight/obesity with type 1 diabetes (T1D) and expects to initiate a Phase 2 proof-of-concept clinical trial in participants with overweight/obesity with T1D.
  • CT-996 (once-daily oral, small molecule GLP-1 receptor agonist) is currently in a multi-arm, multi-cohort Phase 1 clinical trial in adults with overweight/obesity as well as in patients with T2D.
  • A long-acting peptide tyrosine-tyrosine (PYY) analogue, which is in preclinical development.

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress™ 2023

Retrieved on: 
Thursday, June 15, 2023
University of Oxford, EASL, Obesity, NASH, Clinical trial, Non-alcoholic fatty liver disease, NAFLD, Human body weight, Dietary supplement, Patient

GAITHERSBURG, Md., June 15, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Medical Director, Pinnacle Clinical Research and Adjunct Professor of Medicine, Oxford University, will present the results of its 24-week clinical trial of pemvidutide in the treatment of non-alcoholic fatty liver disease (NAFLD) in an oral presentation at the EASL International Liver Congress™ 2023 in Vienna, Austria. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcohol steatohepatitis (NASH).

Key Points: 
  • Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcohol steatohepatitis (NASH).
  • A copy of the presentation will be accessible on the Events section of the Altimmune website.
  • Altimmune will host a reception in Vienna for NASH KOLs and investors on Thursday, June 22 at 6:30 PM CEST.
  • Please click here if you are interested in attending the reception and to receive additional details.

Fractyl Health to Present Landmark Updates on Revita® and Rejuva® Programs at the 83rd American Diabetes Association

Retrieved on: 
Tuesday, June 13, 2023
Science, Other Science, Biotechnology, Research, Health, Diabetes, Medical Devices, Clinical Trials, Obesity, PM, American Diabetes Association, Therapy, Type 2 diabetes, Type 2, Patient, Human body weight, Insulin, T2D, Pharmaceutical industry, Medical device, Pacific Ocean

Fractyl Health, an organ-editing metabolic therapeutics company pioneering new approaches to prevent and reverse type 2 diabetes (T2D), announced today its participation in the upcoming 83rd Scientific Sessions of the American Diabetes Association, happening June 23-26, 2023, in San Diego, CA, and virtually.

Key Points: 
  • Fractyl Health, an organ-editing metabolic therapeutics company pioneering new approaches to prevent and reverse type 2 diabetes (T2D), announced today its participation in the upcoming 83rd Scientific Sessions of the American Diabetes Association, happening June 23-26, 2023, in San Diego, CA, and virtually.
  • Fractyl Health will present clinical and preclinical updates on its Revita® and Rejuva® programs, respectively.
  • "We look forward to presenting our groundbreaking findings at the ADA Scientific Sessions," said Dr. Harith Rajagopalan, CEO of Fractyl Health.
  • "These updates from our Revita® and Rejuva® programs highlight the transformative potential of our metabolic programs in addressing the root causes of T2D aiming to prevent progression and reverse disease."

8th Canadian Obesity Summit

Retrieved on: 
Thursday, April 13, 2023
Learning, Fairmont, Ministry of Territorial Policy, Obesity, Human body weight, Obesity Canada, Policy, COVID-19, Provincial, Student, Summit, Human, Environmental scanning electron microscope, Nursing

WHAT: Obesity Canada will host the 8th Canadian Obesity Summit, a biennial conference that brings together healthcare professionals, researchers, policy makers and students working in obesity prevention and management for a collegial, engaging learning experience.

Key Points: 
  • WHAT: Obesity Canada will host the 8th Canadian Obesity Summit, a biennial conference that brings together healthcare professionals, researchers, policy makers and students working in obesity prevention and management for a collegial, engaging learning experience.
  • Obesity Treatment and Prevention in Canada: An Environmental Scan of Provincial and Territorial Policies.
  • A Qualitative Study of the Experiences of People with Severe Obesity Who Use Community Health and Long-Term Care Services.
  • Obesity Canada will also be announcing the award winners for the first ever Canadian Obesity Fellowship.

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023

Retrieved on: 
Wednesday, January 4, 2023
Human body weight, NASH, Non-alcoholic fatty liver disease, Trial, NAFLD, Balanced line, Entrepreneurship, Obesity, Conference, Pharmaceutical industry, Patient

GAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Chairman and Co-Founder, Pinnacle Clinical Research and Summit Clinical Research, will deliver an oral presentation of the results of Altimmune’s recently completed 12-week Phase 1b and 12-week extension trials of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD) at the NASH-TAG Conference, which will be held in Park City, UT on January 6-7, 2023.

Key Points: 
  • GAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Chairman and Co-Founder, Pinnacle Clinical Research and Summit Clinical Research, will deliver an oral presentation of the results of Altimmune’s recently completed 12-week Phase 1b and 12-week extension trials of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD) at the NASH-TAG Conference, which will be held in Park City, UT on January 6-7, 2023.
  • Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.
  • Details for the oral presentation are as follows:
    Pemvidutide, a Balanced GLP-1/Glucagon Dual Receptor Agonist, Significantly Reduces Liver Fat, Non-invasive Markers of Fibroinflammation, and Body Weight in Patients with Non-alcoholic Fatty Liver Disease: Results of a Multicenter, Randomized, Double-blind, Placebo-controlled Trial
    Stephen Harrison, M.D., Chairman and Co-Founder of Pinnacle Clinical Research and Summit Clinical Research in San Antonio, TX
    A copy of the presentation will be accessible on the Events section of the Altimmune website.

TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma

Retrieved on: 
Wednesday, November 9, 2022
Risk, Department, Human body weight, Massachusetts General Hospital, Therapy, PD-L1, Company, Security (finance), Recurrence, Pancreatic cancer, Tumor microenvironment, Animation, Immunotherapy, Center, Drug discovery, Biomedicine, RNA, Hospital, Athinoula A. Martinos Center for Biomedical Imaging, U.S. Securities and Exchange Commission, Breast, Cancer, Neoplasm, Transcoding, CEO, Glioblastoma, COVID-19, RNA transfection, Private Securities Litigation Reform Act, MOA, PDAC, Nasdaq, Immortalised cell line, Metastasis, Mouse, Harvard Medical School, Coronavirus, Massachusetts Institute of Technology, GLOBE, Intellectual property, TTX, Technology, Annual report, CRISPR, Sirna, Radiology, Animal, Vaccine

BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported positive preclinical results with its immunotherapy candidate, TTX-siPDL1 , in pancreatic adenocarcinoma.

Key Points: 
  • BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported positive preclinical results with its immunotherapy candidate, TTX-siPDL1 , in pancreatic adenocarcinoma.
  • This is the second drug candidate from TransCodes platform to show positive preclinical results in pancreatic cancer.
  • Pancreatic cancer has proven difficult to treat with conventional drugs and has been resistant to initial immunotherapy approaches.
  • TransCode is an RNA oncology company created on the belief that cancer can be effectively treated using RNA therapeutics.

New Research Finds Consumption of Peanuts Supports Weight Loss, Lowers Blood Pressure and Improves Glucose Levels

Retrieved on: 
Tuesday, July 26, 2022
Food, University of South Australia, Arginine, University, Dietitian, Nutrient, Blood, Hunger, Twitter, Effect, Research, Randomized controlled trial, Meal, Health, Risk, Diet, Nutritional science, Glycemic, Texas Tech University, Multimedia, Food industry, Fasting, Facebook, Glycated hemoglobin, Human body weight, Vitamin, Magnesium, Life, Blood pressure, Diabetes, Mineral, Micronutrient, Consumer, Weight loss, Nut, Medicine, Dietary supplement, Medical device, Vegetable oil, Poultry, Legume, Instagram

ALBANY, Ga., July 26, 2022 /PRNewswire/ -- A recent study from the University of South Australia found daily consumption of lightly salted peanuts twice a day before meals led to weight loss, lowered blood pressure and improved fasting glucose levels [1]. The findings were recently published online in the peer-reviewed journal Nutrients and shared by The Peanut Institute. 

Key Points: 
  • "Peanuts are often avoided when people are trying to lose weight because they believe peanuts contain too many calories.
  • Lower Blood Pressure- Greater systolic blood pressure reductions were seen in the peanut-enriched group than the control group.
  • Peanuts contain one of the highest levels of arginine, an amino acid that helps to dilate blood vessels and lower blood pressure.
  • The Effect of a Peanut-Enriched Weight Loss Diet Compared to a Low-Fat Weight Loss Diet on Body Weight, Blood Pressure, and Glycemic Control: A Randomized Controlled Trial.Nutrients.

Biomea Fusion Selected for Two Oral Presentations at the European Association for the Study of Diabetes Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting, Acute Treatment for Type 2 Diabetes

Retrieved on: 
Friday, July 1, 2022
Human body weight, American Diabetes Association, Patient, Glucose, Annual general meeting, European Association for the Study of Diabetes, GLOBE, Rat, 2021 Essex County Council election, Diabetes, C-peptide, ZDF, RATS, Disease, Association, OGTT, Cancer, Lists of diseases, IND, Fasting, Pioglitazone, Nasdaq, Liraglutide, Board, EASD, STZ, Insulin, Method, Pharmaceutical industry, Medical device, Osteopathic medicine in Canada, Glycated hemoglobin, T2DM

Oral Presentations to include additional data not released in the two posters presented at the American Diabetes Association Scientific Sessions on June 4, 2022.

Key Points: 
  • Oral Presentations to include additional data not released in the two posters presented at the American Diabetes Association Scientific Sessions on June 4, 2022.
  • Both presentations highlight BMF-219s robust and prolonged glycemic control, insulin sensitization, and HbA1c reduction in two preclinical rat models of diabetes.
  • These preclinical data support the potential utility of BMF-219 as a novel and acutely dosed oral, long-acting treatment for type 2 diabetes.
  • We are honored to be selected for two oral presentations at the European Association for the Study of Diabetes Annual Meeting.